Announcements Trials
Browse Landscape

Phase

Phase 3 21Phase 2 21Phase 1/2 8Phase 1 7Phase NA 3Phase EARLY_PHASE1 2Phase 2/3 2Phase 4 1

Status

Recruiting 3Not yet recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 3

Conditions

Immunoglobulin Light-chain Amyloidosis 2Neoplasm, Residual 1Multiple Myeloma 1

Interventions

Blood Specimen Collection 104Standard of Care 79Exercise 67Radiotherapy 53Radiosurgery 48Specimen Handling 45Magnetic Resonance Spectroscopy 45Surveys and Questionnaires 44Interviews as Topic 44Practice Guidelines as Topic 43Educational Status 43Methods 41Drug Therapy 35Early Intervention, Educational 30Surgical Procedures, Operative 29Palliative Care 25Control Groups 25Biopsy 24Patient Navigation 18venetoclax 17Cisplatin 17Therapeutics 16Resistance Training 16Proton Therapy 15Magnetic Resonance Imaging 15Behavior Therapy 15Neoadjuvant Therapy 13Cognitive Behavioral Therapy 13Acupuncture Therapy 13Nutritional Status 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase NA × Recruiting × daratumumab × Clear all
NCT06192979 2026-03-09

Optimize First-line Treatment for AL Amyloidosis With t (11; 14)

Peking University People's Hospital

Phase NA Recruiting
41 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis

NCT06697483 2024-11-25

Risk Stratification and MRD-driven Maintenance for MM After ASCT

Peking University People's Hospital

Phase NA Recruiting
100 enrolled
Plasma cell

Multiple Myeloma, Neoplasm, Residual

NCT06455748 2024-06-12

Daratumumab/Daratumumab and Hyaluronidase-fihj in Combination With Pomalidomide and Dexamethasone for the Treatment of Patients With Newly Diagnosed AL Amyloidosis: a Prospective, Multicenter, Single-arm Study

First Affiliated Hospital of Wenzhou Medical University

Phase NA Recruiting
20 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡